226 related articles for article (PubMed ID: 10213792)
1. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
de Tullio P; Delarge J; Pirotte B
Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
[TBL] [Abstract][Full Text] [Related]
2. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.
Beinborn M; Chen C; DeMeo L; McBride EW; Kopin AS
Yale J Biol Med; 1998; 71(3-4):337-46. PubMed ID: 10461364
[TBL] [Abstract][Full Text] [Related]
3. CCK receptor antagonists.
Dunlop J
Gen Pharmacol; 1998 Oct; 31(4):519-24. PubMed ID: 9792209
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic and chemical developments of cholecystokinin receptor ligands.
de Tullio P; Delarge J; Pirotte B
Expert Opin Investig Drugs; 2000 Jan; 9(1):129-46. PubMed ID: 11060666
[TBL] [Abstract][Full Text] [Related]
5. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
[TBL] [Abstract][Full Text] [Related]
6. Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.
Dezube M; Sugg EE; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; James MK; Johnson MF; Mosher JT
J Med Chem; 1995 Aug; 38(17):3384-90. PubMed ID: 7650691
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
Sinha J; Kurup A; Paleti A; Gupta SP
Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
9. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
Harper EA; Griffin EP; Shankley NP; Black JW
Br J Pharmacol; 1999 Mar; 126(6):1496-503. PubMed ID: 10217545
[TBL] [Abstract][Full Text] [Related]
11. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
[TBL] [Abstract][Full Text] [Related]
12. CCK/gastrin antagonists--clinical perspectives.
Calam J
Acta Gastroenterol Belg; 1993; 56(3-4):251-6. PubMed ID: 8266765
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.
Augelli-Szafran CE; Horwell DC; Kneen C; Ortwine DF; Pritchard MC; Purchase TS; Roth BD; Trivedi BK; Hill D; Suman-Chauhan N; Webdale L
Bioorg Med Chem; 1996 Oct; 4(10):1733-45. PubMed ID: 8931944
[TBL] [Abstract][Full Text] [Related]
14. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.
Trivedi BK; Padia JK; Holmes A; Rose S; Wright DS; Hinton JP; Pritchard MC; Eden JM; Kneen C; Webdale L; Suman-Chauhan N; Boden P; Singh L; Field MJ; Hill D
J Med Chem; 1998 Jan; 41(1):38-45. PubMed ID: 9438020
[TBL] [Abstract][Full Text] [Related]
15. CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.
Bläker M; Ren Y; Seshadri L; McBride EW; Beinborn M; Kopin AS
Mol Pharmacol; 2000 Aug; 58(2):399-406. PubMed ID: 10908308
[TBL] [Abstract][Full Text] [Related]
16. [Cholecystokinin receptor antagonists].
Ohtsuka T; Yokose K
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1853-62. PubMed ID: 8210429
[No Abstract] [Full Text] [Related]
17. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a functional role of cholecystokinin receptors in the rat thyroid gland.
Ginda WJ
Folia Histochem Cytobiol; 2001; 39(4):331-4. PubMed ID: 11766768
[TBL] [Abstract][Full Text] [Related]
20. Conformationally restricted analogues of the potent CCK-B antagonist CI-988.
Higginbottom M; Hill DR; Horwell DC; Mostafai E; Suman-Chauhan N; Roberts E
Bioorg Med Chem; 1993 Sep; 1(3):209-17. PubMed ID: 8081854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
